Ter lipresi na m ás a lbúmi na versus mi dodri na y octre óti de m ás a lbúmi na e n e l tratamie nto del s índrome hepatorre nal - F. Mallea C. et al. Medicina Basada en la evidencia en Gastroenterología 101 Referencias 1.- Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P4, Salerno F, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology 2015; 62: 567-74. 2.- Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008; 48: 93-103. 3.- Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7. 4.- Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.Gut 2007; 56: 1310-8. 5.- Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-9. 6.- Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008; 53: 830-5. 7.- Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64. 8.- Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/ Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007; 52: 742-8. 9.- Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7. 10.- Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-76. 11.- Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9. 12.- Centro Cochrane Iberoamericano, traductores. Manual Cochrane de Revisiones Sistemáticas de Intervenciones, versión 5.1.0 actualizada en marzo de 2011 Internet. Barcelona: Centro Cochrane Iberoamericano; 2012. Disponible en http://www.cochrane. es/?q=es/node/269 13.- Candia BR, Letelier SLM, Rada GG. Estudios randomizados interrumpidos precozmente por beneficio: ¿Muy buenos o muy malos? Rev Med Chile 2006; 134: 1470-5. 14.- Brahm J, Quera R. Síndrome Hepatorenal: Patogénesis y Tratamiento. Rev Med Clin Condes 2010; 21: 613-22. Gastroenterol. latinoam 2017; Vol 28, Nº 2: 97-101
gastrolat 2 2017
To see the actual publication please follow the link above